These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 23135987)
1. TEL (ETV6)-AML1 (RUNX1) initiates self-renewing fetal pro-B cells in association with a transcriptional program shared with embryonic stem cells in mice. Tsuzuki S; Seto M Stem Cells; 2013 Feb; 31(2):236-47. PubMed ID: 23135987 [TBL] [Abstract][Full Text] [Related]
2. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. Fischer M; Schwieger M; Horn S; Niebuhr B; Ford A; Roscher S; Bergholz U; Greaves M; Löhler J; Stocking C Oncogene; 2005 Nov; 24(51):7579-91. PubMed ID: 16044150 [TBL] [Abstract][Full Text] [Related]
3. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Tsuzuki S; Seto M; Greaves M; Enver T Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8443-8. PubMed ID: 15155899 [TBL] [Abstract][Full Text] [Related]
4. TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Sabaawy HE; Azuma M; Embree LJ; Tsai HJ; Starost MF; Hickstein DD Proc Natl Acad Sci U S A; 2006 Oct; 103(41):15166-71. PubMed ID: 17015828 [TBL] [Abstract][Full Text] [Related]
5. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Bernardin F; Yang Y; Cleaves R; Zahurak M; Cheng L; Civin CI; Friedman AD Cancer Res; 2002 Jul; 62(14):3904-8. PubMed ID: 12124316 [TBL] [Abstract][Full Text] [Related]
6. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia. Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750 [TBL] [Abstract][Full Text] [Related]
7. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. Ford AM; Palmi C; Bueno C; Hong D; Cardus P; Knight D; Cazzaniga G; Enver T; Greaves M J Clin Invest; 2009 Apr; 119(4):826-36. PubMed ID: 19287094 [TBL] [Abstract][Full Text] [Related]
8. The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL). Lee DS; Kim YR; Cho HK; Lee CK; Lee JH; Cho HI Cancer Genet Cytogenet; 2005 Oct; 162(2):176-8. PubMed ID: 16213368 [TBL] [Abstract][Full Text] [Related]
9. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Hong D; Gupta R; Ancliff P; Atzberger A; Brown J; Soneji S; Green J; Colman S; Piacibello W; Buckle V; Tsuzuki S; Greaves M; Enver T Science; 2008 Jan; 319(5861):336-9. PubMed ID: 18202291 [TBL] [Abstract][Full Text] [Related]
10. A novel TEL-AML1 fusion transcript involving the pro-apoptotic gene BCL-G in pediatric precursor B acute lymphoblastic leukemia. Abdelhaleem M; Yi Q; Beimnet K; Hitzler J Leukemia; 2006 Jul; 20(7):1294. PubMed ID: 16673018 [No Abstract] [Full Text] [Related]
11. Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes. Peter A; Heiden T; Taube T; Körner G; Seeger K Eur J Haematol; 2009 Nov; 83(5):420-32. PubMed ID: 19594616 [TBL] [Abstract][Full Text] [Related]
12. TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression. Asakura K; Uchida H; Miyachi H; Kobayashi H; Miyakawa Y; Nimer SD; Takahashi H; Ikeda Y; Kizaki M Mol Cancer Res; 2004 Jun; 2(6):339-47. PubMed ID: 15235109 [TBL] [Abstract][Full Text] [Related]
13. TEL/AML1 shows dominant-negative effects over TEL as well as AML1. Gunji H; Waga K; Nakamura F; Maki K; Sasaki K; Nakamura Y; Mitani K Biochem Biophys Res Commun; 2004 Sep; 322(2):623-30. PubMed ID: 15325275 [TBL] [Abstract][Full Text] [Related]
14. TEL/AML1-positive patients lacking TEL exon 5 resemble canonical TEL/AML1 cases. Zaliova M; Meyer C; Cario G; Vaskova M; Marschalek R; Stary J; Zuna J; Trka J Pediatr Blood Cancer; 2011 Feb; 56(2):217-25. PubMed ID: 21157892 [TBL] [Abstract][Full Text] [Related]
16. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Zuna J; Ford AM; Peham M; Patel N; Saha V; Eckert C; Köchling J; Panzer-Grümayer R; Trka J; Greaves M Clin Cancer Res; 2004 Aug; 10(16):5355-60. PubMed ID: 15328172 [TBL] [Abstract][Full Text] [Related]
17. RUNX1 aberrations in ETV6/RUNX1-positive and ETV6/RUNX1-negative patients: its hemato-pathological and prognostic significance in a large cohort (619 cases) of ALL. Pais AP; Amare Kadam PS; Raje GC; Banavali S; Parikh P; Kurkure P; Arora B; Gujral S; Kumar SA; Badrinath Y Pediatr Hematol Oncol; 2008 Sep; 25(6):582-97. PubMed ID: 18728978 [TBL] [Abstract][Full Text] [Related]
18. The TEL-AML1 fusion protein of acute lymphoblastic leukemia modulates IRF3 activity during early B-cell differentiation. de Laurentiis A; Hiscott J; Alcalay M Oncogene; 2015 Dec; 34(49):6018-28. PubMed ID: 25893288 [TBL] [Abstract][Full Text] [Related]
19. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Schindler JW; Van Buren D; Foudi A; Krejci O; Qin J; Orkin SH; Hock H Cell Stem Cell; 2009 Jul; 5(1):43-53. PubMed ID: 19570513 [TBL] [Abstract][Full Text] [Related]
20. [The role of TEL and AML1 genes in the pathogenesis of hematologic malignancies]. Zuna J Cas Lek Cesk; 2001 Mar; 140(5):131-7. PubMed ID: 11347199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]